Bristol-Myers Squibb announced a new agreement to expand access to Reyataz(R) (atazanavir sulfate). The immunity-from-suit agreement signed with Matrix Laboratories...enables the generic company to manufacture and sell atazanavir, as well as stavudine and didanosine, in sub-Saharan Africa and India...Frank Pasqualone, president, Intercontinental Region, Bristol-Myers Squibb [said] "Atazanavir is an important component of HIV combination therapy and this agreement facilitates broader availability of the medicine to help ensure patients can access appropriate treatment regimens." The...agreement with Matrix Laboratories is the fifteenth agreement that Bristol-Myers Squibb has signed for its HIV medicines...Under the... agreement, Matrix Laboratories will secure World Health Organization...prequalification for all products covered by the agreement, including pediatric formulations...